BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

886 related articles for article (PubMed ID: 11158206)

  • 1. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
    Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.
    Cattelan AM; Calabro ML; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    Eur J Cancer; 1999 Dec; 35(13):1809-15. PubMed ID: 10673996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.
    Dupin N; Rubin De Cervens V; Gorin I; Calvez V; Pessis E; Grandadam M; Rabian C; Viard JP; Huraux JM; Escande JP
    Br J Dermatol; 1999 May; 140(5):875-81. PubMed ID: 10354025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.
    Pellet C; Chevret S; Blum L; Gauvillé C; Hurault M; Blanchard G; Agbalika F; Lascoux C; Ponscarme D; Morel P; Calvo F; Lebbé C
    J Invest Dermatol; 2001 Oct; 117(4):858-63. PubMed ID: 11676823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients.
    De Milito A; Catucci M; Venturi G; Romano L; Incandela L; Valensin PE; Zazzi M
    J Med Virol; 1999 Feb; 57(2):140-4. PubMed ID: 9892398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
    Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
    AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
    Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
    AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.
    Cattelan AM; Calabrò ML; De Rossi A; Aversa SM; Barbierato M; Trevenzoli M; Gasperini P; Zanchetta M; Cadrobbi P; Monfardini S; Chieco-Bianchi L
    Int J Oncol; 2005 Sep; 27(3):779-85. PubMed ID: 16077928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases.
    Rezza G; Andreoni M; Dorrucci M; Pezzotti P; Monini P; Zerboni R; Salassa B; Colangeli V; Sarmati L; Nicastri E; Barbanera M; Pristerà R; Aiuti F; Ortona L; Ensoli B
    J Natl Cancer Inst; 1999 Sep; 91(17):1468-74. PubMed ID: 10469747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
    Gill J; Bourboulia D; Wilkinson J; Hayes P; Cope A; Marcelin AG; Calvez V; Gotch F; Boshoff C; Gazzard B
    J Acquir Immune Defic Syndr; 2002 Dec; 31(4):384-90. PubMed ID: 12447008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV/AIDS-associated Kaposi's sarcoma with multiple skin-mucosal disseminations following ultraviolet (puva) photochemotherapy.
    Popivanova NI; Chudomirova KN; Baltadzhiev IG; Abadjieva TI
    Folia Med (Plovdiv); 2010; 52(3):56-61. PubMed ID: 21053674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma.
    Tedeschi R; Enbom M; Bidoli E; Linde A; De Paoli P; Dillner J
    J Clin Microbiol; 2001 Dec; 39(12):4269-73. PubMed ID: 11724831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.
    de Souza VA; Pierrotti LC; Sumita LM; Freire WS; Segurado AA; Pannuti CS
    J Med Virol; 2007 Oct; 79(10):1562-8. PubMed ID: 17705173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.
    Borok M; Fiorillo S; Gudza I; Putnam B; Ndemera B; White IE; Gwanzura L; Schooley RT; Campbell TB
    Clin Infect Dis; 2010 Aug; 51(3):342-9. PubMed ID: 20572760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
    Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
    AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.
    Stebbing J; Wildfire A; Portsmouth S; Powles T; Thirlwell C; Hewitt P; Nelson M; Patterson S; Mandalia S; Gotch F; Gazzard BG; Bower M
    Ann Oncol; 2003 Nov; 14(11):1660-6. PubMed ID: 14581275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma.
    Sirianni MC; Vincenzi L; Topino S; Giovannetti A; Mazzetta F; Libi F; Scaramuzzi D; Andreoni M; Pinter E; Baccarini S; Rezza G; Monini P; Ensoli B
    Eur J Immunol; 2002 Oct; 32(10):2711-20. PubMed ID: 12355422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy.
    Aboulafia DM
    Mayo Clin Proc; 1998 May; 73(5):439-43. PubMed ID: 9581584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.